Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
June 24, 2019
Affimed’s approach to advancing immuno-oncology
Our Mission
With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.
Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.
Our Approach
With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.
We have used our extensive drug development expertise to generate antibody candidates tailored to different indications, leveraging our proprietary ROCK® platform. ROCK® enables generation of antibodies with the potential for competitive advantages over traditional therapies including highly customizable antibody engagers for tailored treatment options and generation of antibodies with variable pharmacokinetic (PK) profiles.
Our Pipeline
A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.
Innate Cell Engagers